Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review
Portfolio Pulse from Vandana Singh
Viatris Inc reported Q2 FY23 sales of $3.91 billion, up 2% on a divestiture-adjusted operational basis, slightly higher than the consensus of $3.89 billion. The company generated approximately $124 million in new product revenues in Q2, primarily driven by lenalidomide in the U.S. It reported an adjusted EPS of $0.75, better than the consensus of $0.71. The FDA accepted for review Viatris and Mapi Pharma's New Drug Application for GA Depot 40 mg, a therapy for multiple sclerosis. VTRS shares are up 7.32%.
August 07, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Viatris reported better than expected Q2 FY23 sales and EPS. The FDA's acceptance of the new drug application for a multiple sclerosis therapy could potentially boost future revenues.
Viatris' better than expected Q2 FY23 sales and EPS indicate a strong financial performance. The FDA's acceptance of the new drug application for a multiple sclerosis therapy could potentially lead to increased revenues in the future, which would likely have a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100